bupropion has been researched along with Body Weight in 36 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
Excerpt | Relevance | Reference |
---|---|---|
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks." | 9.24 | Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017) |
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs." | 9.17 | Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013) |
" We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants." | 9.09 | Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001) |
"Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking." | 8.81 | Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002) |
" Sustained-release bupropion (bupropion SR) is the first non-nicotine pharmacological treatment approved for smoking cessation." | 8.81 | Clinical efficacy of bupropion in the management of smoking cessation. ( Jorenby, D, 2002) |
", with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e." | 7.79 | Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. ( Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C, 2013) |
"Bupropion treatment was rarely accompanied by reports of appetite change and had no statistically significant effect on caloric intake when compared to placebo." | 6.65 | Effects of bupropion on body weight. ( Cato, AE; Harto-Truax, N; Miller, LL; Sato, TL; Stern, WC, 1983) |
"The relationship between seizure occurrence and use of bupropion was examined on the basis of manufacturer's reports." | 6.38 | Seizures and bupropion: a review. ( Davidson, J, 1989) |
"This study assessed the effects of 32 mg naltrexone sustained release (SR)/360 mg bupropion SR (NB) on body weight in adults with obesity, with comprehensive lifestyle intervention (CLI), for 78 weeks." | 5.24 | Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. ( Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B, 2017) |
"To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs." | 5.17 | Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013) |
"In people with elevated blood pressure, orlistat, phentermine/topiramate and naltrexone/bupropion reduced body weight; the magnitude of the effect was greatest with phentermine/topiramate." | 5.12 | Long-term effects of weight-reducing drugs in people with hypertension. ( Berghold, A; Horvath, K; Jeitler, K; Krenn, C; Semlitsch, T; Siebenhofer, A; Winterholer, S, 2021) |
" In this study of a 12-week randomized trial of nicotine inhaler, bupropion or both for smoking cessation, 50% of the 1012 female smokers and 26% of the 680 male smokers, at study entry, were weight concerned." | 5.12 | The prevalence of weight concerns in a smoking abstinence clinical trial. ( Bernath, A; Clark, MM; Croghan, GA; Croghan, IT; Dakhil, SR; Ebbert, LP; Garneau, S; Hurt, RD; Loprinzi, CL; Morton, RF; Novotny, P; Patten, CA; Rowland, KM; Sloan, JA; Stella, PJ; Thomas, SP; Tschetter, LK; Wender, DB; Wos, EJ, 2006) |
" We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants." | 5.09 | Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001) |
"Smoking cessation trials of sustained-release bupropion (bupropion SR) were initially conducted in a general population of smokers who were motivated to quit smoking." | 4.81 | Use of sustained-release bupropion in specific patient populations for smoking cessation. ( Tonstad, S, 2002) |
" Sustained-release bupropion (bupropion SR) is the first non-nicotine pharmacological treatment approved for smoking cessation." | 4.81 | Clinical efficacy of bupropion in the management of smoking cessation. ( Jorenby, D, 2002) |
" This analysis looked at the add-on of NB to incretins to see if weight loss could occur in patients already stabilized on incretin agents." | 4.02 | Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. ( Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P, 2021) |
", with naltrexone) has been explored as an anti-obesity strategy, and is particularly effective when co-administered with dual inhibitors of dopamine and norepinephrine reuptake (e." | 3.79 | Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models. ( Athanacio, J; Clapper, JR; D'Souza, L; Griffin, PS; Parkes, DG; Roth, JD; Wittmer, C, 2013) |
"Bupropion treatment was rarely accompanied by reports of appetite change and had no statistically significant effect on caloric intake when compared to placebo." | 2.65 | Effects of bupropion on body weight. ( Cato, AE; Harto-Truax, N; Miller, LL; Sato, TL; Stern, WC, 1983) |
"Treating tobacco dependence is effective in patients with SMI." | 2.46 | Smoking cessation in severe mental illness: what works? ( Banham, L; Gilbody, S, 2010) |
"Bupropion is presumed to be a dopamine-norepinephrine reuptake inhibitor and is an effective antidepressant." | 2.44 | Bupropion: a review of its use in the management of major depressive disorder. ( Curran, MP; Dhillon, S; Yang, LP, 2008) |
"The relationship between seizure occurrence and use of bupropion was examined on the basis of manufacturer's reports." | 2.38 | Seizures and bupropion: a review. ( Davidson, J, 1989) |
"Corticosterone treatment resulted in marked adrenal atrophy and flattening of the glucocorticoid rhythm as measured by repeated blood sampling." | 1.35 | Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder. ( Fairchild, G; Gartside, SE; Ingram, CD; McQuade, R; Minton, GO; Young, AH, 2009) |
"Because obesity can affect catecholaminergic signaling, we determined the effects of i." | 1.34 | Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. ( Billes, SK; Cowley, MA, 2007) |
"Rehabilitation of COPD-patients is an important part of the therapeutic management." | 1.33 | [COPD-rehabilitation]. ( Lichtenschopf, A; Zwick, H, 2005) |
"Bipolar affective disorders can be successfully treated with long-term use of the mood stabilizer lithium." | 1.33 | Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat. ( Ferrie, L; McQuade, R; Young, AH, 2005) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 9 (25.00) | 18.7374 |
1990's | 3 (8.33) | 18.2507 |
2000's | 14 (38.89) | 29.6817 |
2010's | 6 (16.67) | 24.3611 |
2020's | 4 (11.11) | 2.80 |
Authors | Studies |
---|---|
Roberto da Silva, G | 1 |
Carneiro, MG | 1 |
Barbosa, MP | 1 |
Costa, JA | 1 |
de Souza, IA | 1 |
Dos Santos Oliveira, L | 1 |
de Vasconcelos, DAA | 1 |
do Nascimento, E | 1 |
Matos, RJB | 1 |
Lopes de Souza, S | 1 |
de Freitas, MFL | 1 |
Grilo, CM | 1 |
Lydecker, JA | 1 |
Morgan, PT | 1 |
Gueorguieva, R | 1 |
Siebenhofer, A | 1 |
Winterholer, S | 1 |
Jeitler, K | 1 |
Horvath, K | 1 |
Berghold, A | 1 |
Krenn, C | 1 |
Semlitsch, T | 1 |
Wharton, S | 1 |
Yin, P | 1 |
Burrows, M | 1 |
Gould, E | 1 |
Blavignac, J | 1 |
Christensen, RAG | 1 |
Kamran, E | 1 |
Camacho, F | 1 |
Barakat, M | 1 |
Hollander, P | 1 |
Gupta, AK | 1 |
Plodkowski, R | 1 |
Greenway, F | 1 |
Bays, H | 1 |
Burns, C | 1 |
Klassen, P | 1 |
Fujioka, K | 2 |
Halseth, A | 1 |
Shan, K | 1 |
Walsh, B | 1 |
Gilder, K | 1 |
Kapoor, S | 1 |
Minton, GO | 1 |
Young, AH | 2 |
McQuade, R | 2 |
Fairchild, G | 1 |
Ingram, CD | 1 |
Gartside, SE | 1 |
Banham, L | 1 |
Gilbody, S | 1 |
Bray, GA | 1 |
Ryan, DH | 1 |
Levine, MD | 1 |
Cheng, Y | 1 |
Kalarchian, MA | 1 |
Perkins, KA | 1 |
Marcus, MD | 1 |
Clapper, JR | 1 |
Athanacio, J | 1 |
Wittmer, C | 1 |
Griffin, PS | 1 |
D'Souza, L | 1 |
Parkes, DG | 1 |
Roth, JD | 1 |
Tonstad, S | 1 |
Jorenby, D | 1 |
Carter, GT | 1 |
Yudkowsky, MP | 1 |
Han, JJ | 1 |
McCrory, MA | 1 |
Zwick, H | 1 |
Lichtenschopf, A | 1 |
Ferrie, L | 1 |
Clark, MM | 2 |
Hays, JT | 1 |
Vickers, KS | 1 |
Patten, CA | 2 |
Croghan, IT | 2 |
Berg, E | 1 |
Wadewitz, S | 1 |
Schwartz, S | 1 |
Decker, PA | 1 |
Offord, KP | 1 |
Squires, RW | 1 |
Hurt, RD | 2 |
Novotny, P | 1 |
Sloan, JA | 1 |
Dakhil, SR | 1 |
Croghan, GA | 1 |
Wos, EJ | 1 |
Rowland, KM | 1 |
Bernath, A | 1 |
Morton, RF | 1 |
Thomas, SP | 1 |
Tschetter, LK | 1 |
Garneau, S | 1 |
Stella, PJ | 1 |
Ebbert, LP | 1 |
Wender, DB | 1 |
Loprinzi, CL | 1 |
Modell, JG | 1 |
Rosenthal, NE | 1 |
Harriett, AE | 1 |
Krishen, A | 1 |
Asgharian, A | 1 |
Foster, VJ | 1 |
Metz, A | 1 |
Rockett, CB | 1 |
Wightman, DS | 1 |
Billes, SK | 1 |
Cowley, MA | 1 |
Hsieh, YS | 1 |
Yang, SF | 1 |
Chiou, HL | 1 |
Kuo, DY | 1 |
Dhillon, S | 1 |
Yang, LP | 1 |
Curran, MP | 1 |
Davidson, J | 2 |
Miller, R | 1 |
Van Wyck Fleet, J | 1 |
Strickland, R | 1 |
Manberg, P | 1 |
Allen, S | 1 |
Parrott, R | 1 |
Shopsin, B | 1 |
Gardner, EA | 2 |
Harto-Truax, N | 1 |
Stern, WC | 2 |
Miller, LL | 2 |
Sato, TL | 1 |
Cato, AE | 1 |
Feighner, JP | 2 |
Meredith, CH | 1 |
Hendrickson, G | 2 |
Callaghan, RS | 1 |
Chengappa, KN | 1 |
Kambhampati, RK | 1 |
Perkins, K | 1 |
Nigam, R | 1 |
Anderson, T | 1 |
Brar, JS | 1 |
Vemulapalli, HK | 1 |
Atzert, R | 1 |
Key, P | 1 |
Kang, JS | 1 |
Levine, J | 1 |
Johnston, JA | 1 |
Batey, SR | 1 |
Khayrallah, MA | 1 |
Ascher, JA | 1 |
Lineberry, CG | 1 |
Yutrzenka, GJ | 1 |
Patrick, GA | 1 |
Rosenberger, W | 1 |
Wright, G | 1 |
Galloway, L | 1 |
Kim, J | 1 |
Dalton, M | 1 |
Miller, L | 2 |
Stern, W | 2 |
Feighner, J | 1 |
Nobrega, JN | 1 |
Coscina, DV | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo[NCT02317744] | 22 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus[NCT00474630] | Phase 3 | 505 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
A Multicenter, Randomized, Open-Label, Controlled, Method-of-Use Study Assessing the Effect of Naltrexone Sustained Release (SR)/Bupropion SR on Body Weight and Cardiovascular Risk Factors in Overweight and Obese Subjects (The Ignite Study)[NCT01764386] | Phase 3 | 242 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
Effectiveness of a Smoking Cessation Quit Line for Mental Health Patients: Pragmatic Clinical Trial[NCT03230955] | 300 participants (Actual) | Interventional | 2017-05-02 | Completed | |||
Randomized Placebo-Controlled Trial of Ramelteon in the Treatment of Sleep and Mood in Patients With Seasonal Affective Disorder[NCT00502320] | Phase 4 | 50 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
Acute Efficacy of Bupropion, Sertraline, and Venlafaxine as Adjuvant Treatment to Mood Stabilizers in Bipolar Depression: A Randomized, Double-Blind, Comparative Study[NCT00001483] | Phase 2 | 75 participants | Interventional | 1995-06-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)
Intervention | binge eating days (out of 28) (Mean) |
---|---|
Naltrexone/ Bupropion Combination | 5.4 |
Pill Placebo | 2.9 |
Binge eating will be assessed by interview and self-report and the primary outcome is frequency. Frequency also is defined continuously (analyzed dimensionally). (NCT02317744)
Timeframe: Post-treatment (at 3 months)
Intervention | binge eating days (out of 28) (Mean) |
---|---|
Naltrexone/ Bupropion Combination | 4.4 |
Pill Placebo | 3.0 |
BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: 6 month follow-up (an average of 6 months following treatment)
Intervention | kg/m^2 (Mean) |
---|---|
Naltrexone/ Bupropion Combination | 35.9 |
Pill Placebo | 40.3 |
BMI is calculated using measured height and weight. (NCT02317744)
Timeframe: Post-treatment (at 3 months)
Intervention | kg/m^2 (Mean) |
---|---|
Naltrexone/ Bupropion Combination | 34.5 |
Pill Placebo | 39.7 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 18.49 |
Placebo | 5.66 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | -1.06 |
Placebo | -1.47 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -11.87 |
Placebo | -4.02 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | 3.03 |
Placebo | -0.29 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -13.48 |
Placebo | -10.35 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB32 | -1.44 |
Placebo | -0.01 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -11.20 |
Placebo | -0.80 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -1.48 |
Placebo | -1.52 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -1.97 |
Placebo | -2.40 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent (Least Squares Mean) |
---|---|
NB32 | -0.63 |
Placebo | -0.14 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -20.91 |
Placebo | -13.29 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percent change (Least Squares Mean) |
---|---|
NB32 | -20.56 |
Placebo | -14.67 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 0.01 |
Placebo | -1.60 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | 9.27 |
Placebo | 7.90 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB32 | -11.89 |
Placebo | -6.91 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB32 | 0.03 |
Placebo | -1.12 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | cm (Least Squares Mean) |
---|---|
NB32 | -4.97 |
Placebo | -2.89 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of body weight (Least Squares Mean) |
---|---|
NB32 | -5.03 |
Placebo | -1.75 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 44.53 |
Placebo | 18.87 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 20.72 |
Placebo | 10.22 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 44.14 |
Placebo | 26.28 |
Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control. (NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 0 |
Placebo | 1.89 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 22.26 |
Placebo | 35.22 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 3.02 |
Placebo | 1.26 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
Intervention | percentage of participants (Number) |
---|---|
NB32 | 1.89 |
Placebo | 1.26 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | kg (Least Squares Mean) |
---|---|
NB + CLI | -9.7 |
Usual Care | -1.0 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | uIU/mL (Least Squares Mean) |
---|---|
NB + CLI | -7.5 |
Usual Care | -3.4 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB + CLI | -1.7 |
Usual Care | -1.3 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | 4.1 |
Usual Care | 0.1 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | -2.0 |
Usual Care | -1.9 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | -2.9 |
Usual Care | 1.6 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mg/dL (Least Squares Mean) |
---|---|
NB + CLI | -13.6 |
Usual Care | 2.8 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | bpm (Least Squares Mean) |
---|---|
NB + CLI | 1.7 |
Usual Care | -0.3 |
HOMA-IR is an insulin sensitivity index that is calculated as HOMA-IR = (Glucose * Insulin) / 405, where glucose is in mass units (mg/dL) and insulin is in µIU/mL. Higher values indicate lower insulin sensitivity. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | -2.0 |
Usual Care | -0.8 |
Arizona Sexual Experiences (ASEX) scale is a 5-item rating scale that quantifies sex drive, arousal, vaginal lubrication/penile erection, ability to reach orgasm, and satisfaction from orgasm. Possible total scores range from 5 to 30, with the higher scores indicating more sexual dysfunction. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | -2.2 |
Usual Care | -0.1 |
The BES is a 16-item questionnaire that identifies different levels of binge-eating severity, with total scores ranging between 0-46. BES scores were categorized as follows: None = Scores ≤17 indicated no significant binge eating, Moderate = scores from 18 to 26 (inclusive), Severe = scores ≥27 indicated severe levels of binge eating. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | -6.8 |
Usual Care | 1.1 |
Impact of Weight on Quality of Life-Lite Questionnaire (IWQOL-Lite) is a self-reported assessment of perceived effect of weight on quality of life. It consists of 31 items organized in 5 domains (physical function, self-esteem, sexual life, public distress and work). IWQOL-Lite total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment. (NCT01764386)
Timeframe: Baseline to Week 26
Intervention | units on a scale (Least Squares Mean) |
---|---|
NB + CLI | 16.4 |
Usual Care | -1.0 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | mm Hg (Least Squares Mean) |
---|---|
NB + CLI | -4.8 |
Usual Care | -2.8 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | cm (Least Squares Mean) |
---|---|
NB + CLI | -6.96 |
Usual Care | -1.64 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percent change in body weight (Least Squares Mean) |
---|---|
NB + CLI | -9.46 |
Usual Care | -0.94 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percentage of participants (Number) |
---|---|
NB + CLI | 42.3 |
Usual Care | 3.7 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percentage of participants (Number) |
---|---|
NB + CLI | 12.7 |
Usual Care | 0.0 |
(NCT01764386)
Timeframe: Baseline to Week 26
Intervention | percentage of participants (Number) |
---|---|
NB + CLI | 84.5 |
Usual Care | 12.2 |
Clinician-rated measure of mood; evaluates classical 21 Hamilton Depression items, and 8-item subscale measuring atypical depression symptoms which commonly occur during SAD episodes. Score ranges from 0-89, higher scores indicate higher levels of depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
Intervention | scores on a scale (Mean) | ||||
---|---|---|---|---|---|
Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
Placebo | 19.99 | 15.97 | 19.47 | 20.65 | 23.68 |
Ramelteon | 22.68 | 16.16 | 14.81 | 11.69 | 9.15 |
Self-rated scale to measure severity of depressive symptoms. Score ranges from 25-100, higher scores reflect more depression. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
Intervention | scores on a scale (Mean) | ||||
---|---|---|---|---|---|
Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
Placebo | 58.63 | 56.40 | 58.59 | 58.62 | 61.65 |
Ramelteon | 63.06 | 54.35 | 53.51 | 49.26 | 46.14 |
Self-rated scale to measure quality of sleep via questions regarding sleep latency, duration, efficiency, disturbances, use of sleep medication, and daytime dysfunction. Score ranges from 0-21, higher scores represent more significant sleep disturbance. (NCT00502320)
Timeframe: Monthly for duration of treatment (up to 4 months)
Intervention | scores on a scale (Mean) | ||||
---|---|---|---|---|---|
Baseline | Month 1 | Month 2 | Month 3 | Month 4 | |
Placebo | 11.45 | 8.67 | 8.62 | 9.88 | 9.61 |
Ramelteon | 11.56 | 9.52 | 7.57 | 8.07 | 7.05 |
6 reviews available for bupropion and Body Weight
Article | Year |
---|---|
Long-term effects of weight-reducing drugs in people with hypertension.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Bias; Blood Pressure; Body Weight; Bupropion; Diet | 2021 |
Smoking cessation in severe mental illness: what works?
Topics: Adult; Behavior Therapy; Body Weight; Bupropion; Dopamine Uptake Inhibitors; Female; Healthcare Disp | 2010 |
Use of sustained-release bupropion in specific patient populations for smoking cessation.
Topics: Alcoholism; Body Weight; Bupropion; Delayed-Action Preparations; Depression; Dopamine Uptake Inhibit | 2002 |
Clinical efficacy of bupropion in the management of smoking cessation.
Topics: Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Drug Administration | 2002 |
Bupropion: a review of its use in the management of major depressive disorder.
Topics: Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Citalopram; Delayed-Action Prepara | 2008 |
Seizures and bupropion: a review.
Topics: Adolescent; Adult; Age Factors; Aged; Antidepressive Agents; Body Weight; Bupropion; Cohort Studies; | 1989 |
15 trials available for bupropion and Body Weight
Article | Year |
---|---|
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study.
Topics: Adult; Anti-Obesity Agents; Binge-Eating Disorder; Body Weight; Bupropion; Double-Blind Method; Drug | 2021 |
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupro | 2013 |
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity.
Topics: Adolescent; Adult; Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; | 2017 |
Dietary intake after smoking cessation among weight-concerned women smokers.
Topics: Body Weight; Bupropion; Diet; Eating; Female; Humans; Smoking; Smoking Cessation; Weight Gain | 2012 |
Body image treatment for weight concerned smokers: a pilot study.
Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Body Image; Body Weight; Bupropion; Cognit | 2005 |
The prevalence of weight concerns in a smoking abstinence clinical trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Image; Body Weight; Bupropion; Female; Humans; | 2006 |
Seasonal affective disorder and its prevention by anticipatory treatment with bupropion XL.
Topics: Adult; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Double-Blind Method; Drug A | 2005 |
A double-blind comparison of bupropion and amitriptyline in depressed inpatients.
Topics: Adult; Amitriptyline; Antidepressive Agents; Appetite; Body Weight; Bupropion; Clinical Trials as To | 1983 |
Bupropion: a new clinical profile in the psychobiology of depression.
Topics: Antidepressive Agents; Bipolar Disorder; Body Weight; Bupropion; Clinical Trials as Topic; Depressiv | 1983 |
Effects of bupropion on body weight.
Topics: Amitriptyline; Antidepressive Agents; Appetite; Body Weight; Bupropion; Clinical Trials as Topic; Do | 1983 |
A double-blind study of bupropion and placebo in depression.
Topics: Adult; Aged; Antidepressive Agents; Body Weight; Bupropion; Clinical Trials as Topic; Depressive Dis | 1984 |
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Bupropion; Comorbidity; Delayed-Action Prepar | 2001 |
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Body Weight; Bupropion; Depressive Disorder; Dose-Res | 1991 |
Bupropion in the long-term treatment of cyclic mood disorders: mood stabilizing effects.
Topics: Adult; Antidepressive Agents; Antipsychotic Agents; Bipolar Disorder; Body Weight; Bupropion; Chroni | 1985 |
Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Body Weight; Bupropion; Clinical Trials as Topic; Depressive Dis | 1986 |
15 other studies available for bupropion and Body Weight
Article | Year |
---|---|
Naltrexone/bupropion modifies weight, food intake, and Drd2 gene expression in rats.
Topics: Animals; Body Weight; Bupropion; Diet, High-Fat; Eating; Gene Expression; Naltrexone; Obesity; Rats; | 2022 |
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial.
Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypogl | 2021 |
Strategies to control antipsychotic-induced weight gain.
Topics: Anti-Obesity Agents; Antipsychotic Agents; Awareness; Body Weight; Bupropion; Clinical Competence; F | 2008 |
Profound changes in dopaminergic neurotransmission in the prefrontal cortex in response to flattening of the diurnal glucocorticoid rhythm: implications for bipolar disorder.
Topics: Adrenal Glands; Animals; Anti-Inflammatory Agents; Body Weight; Bupropion; Circadian Rhythm; Cortico | 2009 |
Drug treatment of obesity.
Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupro | 2011 |
Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.
Topics: Animals; Appetite Depressants; Body Composition; Body Weight; Bupropion; Diet; Drug Interactions; Ea | 2013 |
Topiramate for weight reduction in Duchenne muscular dystrophy.
Topics: Adolescent; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Appetite; Body Weight; Bu | 2005 |
[COPD-rehabilitation].
Topics: Acupuncture Therapy; Adrenergic alpha-Agonists; Antidepressive Agents, Second-Generation; Antidepres | 2005 |
Effect of chronic lithium and withdrawal from chronic lithium on presynaptic dopamine function in the rat.
Topics: Animals; Body Weight; Bupropion; Chromatography, High Pressure Liquid; Dopamine; Dopamine Plasma Mem | 2005 |
Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.
Topics: Animals; Behavior, Animal; Body Weight; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drug | 2007 |
Roles of central catecholamine and hypothalamic neuropeptide Y genome in the development of tolerance to phenylpropanolamine-mediated appetite suppression.
Topics: Amphetamine; Animals; Appetite Depressants; Body Weight; Bupropion; Catecholamines; Catheterization; | 2007 |
Long-term preventive care in depression: the use of bupropion in patients intolerant of other antidepressants.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Tricyclic; Body Weight; | 1983 |
Appetite and weight in children treated for ADHD.
Topics: Appetite Regulation; Attention Deficit Disorder with Hyperactivity; Body Weight; Bupropion; Central | 1999 |
Substitution of psychoactive drugs in pentobarbital-dependent rats.
Topics: Animals; Antidepressive Agents; Arousal; Body Weight; Brain; Bromazepam; Bupropion; Diazepam; Dose-R | 1990 |
Dopamine-norepinephrine interactions in the development of hyperphagia and obesity following medial hypothalamic lesions.
Topics: Animals; Body Weight; Brain Mapping; Bupropion; Dopamine; Feeding Behavior; Female; Hydroxydopamines | 1986 |